These antibody-based analyses confirmed that the candidate biomarkers, AACT and C4BPα, exhibit variation patterns in agreement with MS results, although significant differences were only found when comparing Controls versus AD cases from the UMG-cohort. The gene discussed is C4BPA; the disease is Alzheimer disease.